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Abstract
Background: Diminished IL-2 production and lack of effector differentiation have been reported
for HIV-specific T cells. In this study, we examined the prevalence of these phenomena using 8-
color cytokine flow cytometry, and tested the hypothesis that these two findings were causally
related. We analyzed cytokine profiles and memory/effector phenotypes of HIV-specific and CMV-
specific T cells using short-term in vitro stimulation with HIV or CMV peptide pools. Nineteen HIV-
positive subjects with progressive disease and twenty healthy, HIV-negative subjects were
examined.
Results:  Among HIV-infected subjects, there were significantly fewer CD8+ IL-2+ T cells
responding to HIV compared to CMV, with no significant difference in CD4+ IL-2+ T cells. The
majority of CMV-specific T cells in both HIV-negative and HIV-positive subjects appeared to be
terminally differentiated effector cells (CD8+ CD27- CD28- CD45RA+ or CD8+ CD27- CD28-
CD45RA-). In HIV-positive subjects, the most common phenotype of HIV-specific T cells was
intermediate in differentiation (CD8+ CD27+ CD28- CD45RA-). These differences were
statistically significant, both as absolute cell frequencies and as percentages. There was a significant
correlation between the absolute number of HIV-specific CD8+ IL-2+ T cells and HIV-specific
CD8+ CD27- CD28- CD45RA+ terminal effector cells.
Conclusion: IL-2 production from antigen-specific CD8+ T cells correlates with effector cell
differentiation of those cells.
Background
The phenotype of CD4+ and CD8+ T cells responding to
pathogens such as HIV or CMV is at least partially linked
with their functions, which include cytokine production
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and cytotoxicity. In chronic HIV infection, the functional
profile of HIV-specific T cells has been reported to be
impaired in a variety of ways, including the ability to pro-
duce IL-2 [1-10]. This defect has been reported to apply to
CD4+ [1,2,4,5,9,11] and CD8+ [3,6-8,10] T cells by differ-
ent investigators.
Other studies have reported differences in the phenotype
of HIV-specific CD8+ T cells compared to CMV-specific
CD8+ T cells in subjects with chronic HIV infection [12-
18]. In particular, a disproportionate number of cells of
"intermediate" differentiation can be found among HIV-
specific CD8+ T cells [12,17,18]. These "intermediate"
cells have been variously described as CD27+ CD28- [12]
and CCR7- CD45RA- [17,18], whereas most CMV-specific
CD8+ T cells are terminally differentiated effector cells
(CCR7- CD27- CD28- CD45RA+). A similar phenome-
non of incomplete differentiation has been described for
HIV-specific CD4+ T cells [19]. However, the prevalence
of these differentiation "defects" among HIV+ individuals
with progressive disease has not been well-defined. Fur-
thermore, the relationship between differentiation state
and IL-2 production has not been explored for either
CD4+ or CD8+ HIV-specific T cells.
IL-2 is important for the survival and proliferation of acti-
vated T cells (reviewed in [20]). However, it has also been
hypothesized to contribute to the differentiation of termi-
nal effector CD8+ T cells in acute hepatitis C infection
[21]. We reasoned that it was possible that a similar rela-
tionship might exist in chronic HIV infection, such that
the independently observed defects in IL-2 production
and differentiation of HIV-specific T cells might be associ-
ated.
To test this hypothesis, we simultaneously analyzed the
cytokine production and phenotype of HIV-specific and
CMV-specific T cells from a cohort of HIV-positive sub-
jects with progressive disease, as well as CMV-specific T
cells from HIV-negative subjects. We did short-term stim-
ulation of PBMC with mixtures of peptides spanning mul-
tiple immunogenic proteins from HIV or CMV, then did a
combined analysis for IFNγ and IL-2, as well as for CD27,
CD28, and CD45RA. Results for each possible phenotype
of cytokine-positive cells were expressed both as a percent-
age of CD4+ or CD8+ T cells and as an absolute number
of cells per ml. Our simultaneous analysis of differentia-
tion and function of HIV-specific and CMV-specific T cells
allowed for the ability to see whether changes in differen-
tiation were correlated with changes in function, for either
CD4+ and/or CD8+ T cells.
Results
Stability of effector/memory markers in short-term 
stimulation
We simultaneously analyzed cytokine production and
effector/memory markers of CMV- and HIV-responsive T
cells using the gating strategy shown in Figure 1, in a
cohort of 19 HIV-positive subjects with progressive dis-
ease and 20 healthy controls (Table 1). Since activation of
T cells was required to detect cytokine production, we
wanted to ensure that the phenotypic markers examined
did not modulate during short-term stimulation. Using an
MHC-peptide tetramer to isolate CMV-specific T cells, we
demonstrated that 6-hour stimulation had minimal effect
on the distribution of CD27, CD28, and CD45RA on
these cells (Figure 2). Therefore, our analysis closely
reflected the in vivo state of differentiation of these cells,
rather than the effects of in vitro stimulation.
Decreased IL-2 production in HIV-specific CD8+ but not 
CD4+ T cells
The magnitude of the T cell IFNγ responses to CMV
pp65+IE-1 and to HIV Gag+Env, as well as the IL-2+ com-
ponent of those responses, is shown in Figure 3 for 20
healthy HIV-negative subjects and 19 HIV-positive pro-
gressors. There were significant differences in the magni-
tude of CMV responses of HIV-negative versus HIV-
positive subjects. These were attributable to differences in
CD4 and CD8 counts between the groups (see next para-
graph). However, the only significant difference in the
magnitude of CMV versus HIV responses of HIV-positive
subjects was a reduced frequency of HIV-specific CD8+ T
cells producing both IFNγ and IL-2 (p = 0.0005).
To determine whether this reduction in CD8+ T cell IL-2
production among HIV-specific T cells was consistent
when data were analyzed on a proportional basis, we
examined the ratio of IL-2+/IFNγ+ T cells responding to
HIV versus CMV (Figure 4). This analysis clearly showed
that the proportion of HIV-specific CD8+ T cells that
could produce IL-2 was significantly reduced compared to
that of CMV-specific CD8+ T cells in HIV-positive subjects
(p = 0.0005). No other significant differences in IL-2+/
IFNγ+ T cell ratios were found.
Incomplete differentiation in HIV-specific CD4+ and CD8+ 
T cells
We next analyzed the differentiation profile of HIV-spe-
cific and CMV-specific T cells in healthy subjects versus
HIV-positive progressors. Several trends were observed.
The response of healthy subjects to CMV (Figure 5A, top
panel) was quite heterogeneous, involving most of the
possible phenotypes of both CD4+ and CD8+ T cells.
However, the CD8+ response was higher than the CD4+
response, and the fraction of IFNγ+ IL-2+ T cells was smallAIDS Research and Therapy 2006, 3:18 http://www.aidsrestherapy.com/content/3/1/18
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Hierarchical gating strategy Figure 1
Hierarchical gating strategy. After applying an acquisition threshold on CD3, gate A was constructed to include CD3 dim cells. 
CD3+ low-scatter cells were identified either as CD4+ CD8- or CD4- CD8+ (gates B and C, which also included dim positive 
cells). Cytokine+ cells in gates B and C were identified either as total IFNγ+ or IFNγ+ IL-2+. These two classes of cytokine-
producing cells were determined to be either CD27- or CD27+, and then further separated by expression of CD28 and 
CD45RA. Gates R through WW represent the 32 ultimate phenotypes compared in this study. The example shown is from a 
pp65+IE-1 stimulated HIV-negative subject.
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compared to total IFNγ+ T cells. Among the CD8+ T cell
phenotypes, terminally-differentiated effector cells pre-
dominated, followed by CD27- CD28- CD45RA- cells.
Thus, the healthy donor response to CMV was highly
skewed towards effector cell phenotypes.
The CMV-specific response of HIV-positive progressors
was similarly skewed towards effector CD8+ IFNγ+ T cells
(Figure 5A, middle panel). The number of CMV-specific
CD4+ T cells was significantly lower in the HIV-positive
subjects, although the distribution of phenotypes was
similar to that of HIV-negative subjects. These differences
were largely a result of reduced CD4+ T cell counts in the
HIV-positive subjects, since the differences were not statis-
tically significant on a percentage basis (Table 2).
The HIV response of HIV-positive progressors (Figure 5A,
bottom panel) was different from the CMV responses in
that it was dominated by CD8+ IFNγ+ T cells of interme-
diate differentiation (CD27+ CD28- CD45RA-). This phe-
notype was rare within the healthy donor CMV response.
Also, the HIV responses contained hardly any CD4+ or
CD8+ IL-2-producing cells, and only very few CD4+
IFNγ+ cells. These differences in CD4 and CD8 compart-
ments were significant by ANOVA (Table 2), with the
most highly significant differences being in the CD8+
IFNγ+ subset (p ≤ 0.00008). These differences were signif-
icant even when subjects receiving ART were excluded
(Table 2, bottom half).
It should be noted that the distribution of CD8+ T cell
phenotypes seen in HIV-responsive cells was not reflected
in the overall CD8+ T cell compartment (Figure 5B). The
total CD8+ T cell pool was quite heterogeneous, and
included a large cohort of effector-like cells (CD27-
CD28- CD45RA+ and CD27- CD28- CD45RA-).
Overall, the data of Table 2 confirm that the differences in
phenotypic patterns observed in the CMV and HIV
responses of HIV-positive progressors were statistically
significant. The most significant difference (p ≤ 0.00008)
was seen in CD8+ IFNγ+ cells. This was true when data
were analyzed as percentages or as absolute counts, and
whether or not subjects on ART were included.
Relationship of phenotype to IL-2 production
The above data demonstrate that HIV-specific CD8+ T
cells in HIV-positive progressors show two major differ-
Table 1: Subject characteristics
HIV-negative subjects HIV-positive subjects
Subject Abs CD41 Abs CD81 Subject Abs CD41 Abs CD81 Viral Load2 ART3
101 1382 1233 1026 299 304 69200 No
105 787 687 1027 543 978 36600 No
107 490 323 1034 330 609 29400 No
111 541 236 1036 433 1259 4880 No
114 686 327 1038 17 159 >500000 No
119 497 184 1059 417 1628 21500 No
120 697 364 1079 381 756 76200 No
121 882 341 1501 493 648 18100 No
124 828 1101 1503 528 1094 8000 No
133 943 900 2008 333 499 5600 No
137 591 516 3002 158 456 21700 No
138 1278 612 3012 312 1138 9000 Yes
142 820 577 3067 60 928 27400 No
144 523 637 3093 560 2431 7300 Yes
148 445 416 3094 190 837 12800 Yes
150 795 868 3102 104 1548 37200 Yes
156 983 951 3114 43 575 16100 No
157 828 766 3114 26 385 9400 No
158 598 525 3168 110 1676 262000 Yes
1075 1092 270 3170 192 750 28200 Yes
mean 7844 5925 mean 2764 9335
1Abs = Absolute Cell Count, as number of cells per microliter of blood.
2Viral Load, as copies per milliliter of blood.
3ART = Currently receiving anti-retroviral therapy.
4Absolute CD4 cell counts of HIV- and HIV+ subjects are significantly different (p < 0.0001).
5Absolute CD8 cell counts of HIV- and HIV+ subjects are significantly different (p = 0.0439).AIDS Research and Therapy 2006, 3:18 http://www.aidsrestherapy.com/content/3/1/18
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Effects of stimulation on memory cell markers Figure 2
Effects of stimulation on memory cell markers. A CMV-positive whole blood sample from a healthy donor was incubated for 
six hours with pp65 peptide, in the presence of brefeldin A. Phenotypic analysis was performed both before and at various time 
points during stimulation. A: Gating on CMV tetramer-positive cells, the response to stimulation after six hours is demon-
strated by the release of cytokine. By isolating the tetramer-positive IFNγ+ cells, it is evident that there are only nominal 
changes in the proportions of memory cell markers after six hour stimulation. B: Changes in each individual phenotype over 
time are shown. Results are expressed as absolute number of cells per milliliter of blood.
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ences compared to CMV-specific CD8+ T cells: (1) a lower
proportion of IL-2-producing cells, and (2) a less differen-
tiated phenotype. We tested two potential hypotheses that
might explain the coexistence of these two phenomena.
The first hypothesis, that the less differentiated CD8+ T
cells tend not to produce IL-2, can be easily dismissed by
examination of IL-2 production as a function of pheno-
type (Figure 6). While IL-2-producing T cells could be
found amongst all phenotypes of CD8+ IFNγ+ T cells spe-
cific for CMV, proportionally fewer cells produced IL-2
upon differentiation to effector phenotypes (Figure 6, top
panel). This pattern was somewhat disrupted in the CMV
response of HIV-positive subjects (middle panel), but the
Responses of cytokine-specific T cells to CMV and HIV stimulation Figure 3
Responses of cytokine-specific T cells to CMV and HIV stimulation. Each symbol represents one patient; mean response is 
shown as a horizontal line. Results are displayed as absolute number of relevant cells (CD4+ IFNγ+, CD4+ IFNγ+ IL-2+, CD8+ 
IFNγ+, or CD8+ IFNγ+ IL-2+) per ml of blood. Subjects and stimuli are listed below the X axis. Statistical comparisons 
between HIV-positive and HIV-negative subjects were performed using a Mann Whitney test. Statistical comparisons between 
different stimulations of HIV-positive samples were performed using a Wilcoxon signed rank test. Values of p < 0.025 were 
considered statistically significant.
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most pronounced difference was observed in the HIV
response (bottom panel). HIV-responsive CD8+ T cells of
all phenotypes essentially did not make IL-2. Thus, there
is a pervasive breakdown in IL-2 production from all HIV-
specific CD8+ T cells, and not simply a replacement of
cells that normally make IL-2 with cells that normally do
not.
HIV-specific defects in differentiation and function are 
correlated
A second hypothesis for the co-existence of fewer CD8+
IL-2+ T cells and altered differentiation in HIV responses
was that IL-2 production is required to drive effector T cell
differentiation. If this were true, one would expect to see a
quantitative correlation between CMV-specific or HIV-
specific T cells and differentiation state. Figure 7A shows
that the number of HIV-specific IFNγ+ IL-2+ CD8+ T cells
is significantly correlated with the number of HIV-specific
CD8+ terminal effector T cells (CD27- CD28- CD45RA+)
(p = 0.0004, top). The correlation remained significant
when CMV-specific responses were also included (p  =
0.0073, bottom). Finally, the correlations remained sig-
nificant (p = 0.03) when frequencies were reported as a
percentage of CD8+ T cells, rather than as absolute counts
(data not shown). Therefore, a greater number of CD8+
IL-2-producing cells correlated with more terminally dif-
ferentiated CD8+ effector cells in the antigen-specific
response.
We also looked at the correlation of CD4+ IL-2-producing
cells with CD8+ effector cells. These were not as well cor-
related for either HIV-specific or pooled HIV-specific and
CMV-specific responses (p  = 0.0743 and p  = 0.0410,
respectively; data not shown). However, when the fre-
quency of all IFNγ+ IL-2+ T cells (CD4+ and CD8+) were
plotted against the frequency of CD8+ terminal effector
cells (Figure 7B), the correlation was highly significant,
both for the HIV-specific stimulation (p = 0.0006, top)
and for pooled HIV-specific and CMV-specific results (p =
0.0034, bottom). This argues strongly for a role of IL-2 in
promoting CD8+ effector T cell differentiation.
Discussion
In this study, we conducted a detailed analysis of the phe-
notypes and functions of HIV-specific and CMV-specific T
cells in subjects with progressive HIV disease, compared
to healthy subjects. By using pools of peptides represent-
ing multiple HIV and CMV antigens, we were able to ana-
lyze a large proportion of the total virus-specific response,
rather than analyzing only single epitope responses. By
pooling the results from approximately 20 subjects in
each group, we reduced bias due to individual differences
within groups, which were large. By determining T-cell
phenotypes using a comprehensive gating hierarchy, we
were able to classify every cell according to one of 32
unique differentiation profiles. This allowed a more
standardized and complete approach than could be
achieved by comparing only a few markers at a time.
By expressing results as absolute counts of CD4+ or CD8+
T-cells, we accounted for the wide variety of absolute
CD4+ T cell counts among our subjects (Table 1). Never-
theless, significant differences between HIV and CMV
responses of HIV-positive progressors remained when
data were analyzed as percentages of CD4+ or CD8+ T
cells (Table 2).
Ratio of IL-2+ to IFNγ+ T cells responding to HIV versus  CMV Figure 4
Ratio of IL-2+ to IFNγ+ T cells responding to HIV versus 
CMV. Each symbol represents one patient; the mean 
response is shown as a horizontal line. Subjects and stimuli 
are listed below the X axis. Statistical comparisons between 
HIV-positive and HIV-negative subjects were performed 
using a Mann Whitney test. Statistical comparisons between 
different stimulations of HIV-positive samples were per-
formed using a Wilcoxon signed rank test. Values of p < 
0.025 were considered statistically significant.
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A: Individual phenotypic responses of HIV-negative and HIV-positive subjects to pp65+IE-1 or Gag+Env stimulation Figure 5
A: Individual phenotypic responses of HIV-negative and HIV-positive subjects to pp65+IE-1 or Gag+Env stimulation. Grey bars 
represent the mean (for 20 HIV-negative or 19 HIV-positive subjects) of the absolute number of cells for each of the 32 pheno-
types, as listed at the bottom of the figure. Black bars represent the background, as mean of the absolute number of cytokine-
positive cells in the unstimulated samples, for each phenotype. In both cases, error bars represent SEM. Phenotypes are 
grouped horizontally as CD4+ or CD8+, and by their cytokine profile. Within each subgroup, phenotypes are arranged from 
naïve (left) to terminal effector (right), with intermediates arranged by order of potential for IL-2 production in healthy donors 
(see Figure 6, top panel). Results are shown for the response of HIV-negative subjects to pp65+IE-1 stimulation (top), the 
response of HIV-positive subjects to pp65+IE-1 stimulation (middle), and the response of HIV-positive subjects to Gag+Env 
stimulation (bottom). B: Individual phenotypes of total CD4+ or CD8+ T cells. Each bar represents the mean (for 19 HIV-pos-
itive subjects) of the absolute number of cells displaying each of the phenotypes, as listed at the bottom of the figure. Error 
bars represent SEM. Results are shown for HIV-positive patient PBMC stimulated with Gag+Env peptide mix, for direct com-
parison to the HIV-specific response shown in A.
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The results of our analysis confirm and extend findings
that were previously reported in separate investigations:
namely, that HIV-specific CD8+ T cells producing IL-2 are
reduced in number and proportion compared to CMV-
specific CD8+ T cells producing IL-2 [3,6-8], and that
effector cell differentiation of CD8+ T cells differs between
HIV and CMV responses [12-17].
Our observation of reduced CD8+ T cell IL-2 production
is consistent with published reports about the lack of pro-
liferative capacity of these cells in progressive HIV disease
[6,15,22]. However, we did not see a similar loss in IL-2-
producing CD4+ T cells specific for HIV as compared to
CMV, which has also been previously reported [1,2,4,5,9].
This could be due to our reporting of these cells on an
absolute count basis. But we also observed no significant
differences in the ratio of IL-2+/IFNγ+ CD4+ T cells
between CMV and HIV responses of HIV-positive progres-
sors. In general, the CD4 responses of this cohort were
very low.
The CMV response of healthy subjects showed the highest
degree of effector cell differentiation among CD8+ T cells,
and these subjects tend to have undetectable CMV viral
loads in blood [23]. By contrast, high HIV viral loads were
present in all of the HIV-positive subjects (Table 1). Yet,
these subjects tended to have fewer CD8+ effector T cells
and more cells of intermediate differentiation. Thus, the
differentiation of the CD4+ and CD8+ T cell response to
HIV can be thought of as defective in HIV-positive pro-
gressors, in that it does not reflect viral load, and does not
result in the effector cells that are associated with control
of CMV viral load in healthy subjects.
We did not observe a significant relationship between HIV
viral load and CD4+ or CD8+ T cell differentiation status
(data not shown). This is in contrast to studies that
showed a relationship between CD4+ T cell differentia-
tion and viral load [2,4,24]. However, these studies all
involved long-term non-progressors or others who con-
trolled viremia, whereas the cohort in the present study
consisted entirely of progressors with viral loads >4800.
Thus, it is certainly plausible that T cell differentiation
becomes "uncoupled" with viral load at some stage of HIV
progression or level of persistent viremia. In fact, our
results would argue that this may occur due to a defect in
IL-2 production, which itself may be a result of persist-
ently high antigen load [25,26].
A recent report has suggested that cells of earlier stages in
CD8+ differentiation (CD28+) are important for control
of CMV [27]. By analogy, HIV-specific CD8+ T cells can
also be thought of as defective, since they are predomi-
nantly CD27+ CD28- CD45RA-. However, the proportion
of all CD8+ CD28+ T cells responding to HIV was not sig-
nificantly different from that responding to CMV in our
study (data not shown). Our data thus do not support a
universal role for CD8+ CD28+ T cells in control of
chronic viral infection.
One might hypothesize that the altered differentiation of
HIV-specific T cells we observed might be related to dis-
ease progression as measured by absolute CD4 count.
However, there was no significant correlation between
CD4 count and CD4+ or CD8+ T cell differentiation status
in this study (data not shown). This suggests that altered
differentiation of HIV-specific T cells may be an addi-
tional marker of disease progression, independent of CD4
count and viral load. In fact, the relationship of viral load,
CD4 count, and HIV-specific T cell responses is complex
[25,26], and large prospective studies will be necessary to
determine causal relationships between them.
Because our analysis combined phenotypes and function,
we were able to ask whether phenotypic and functional
defects were quantitatively related. While a clear relation-
Table 2: Analyses of variance
Absolute Count Percent CD4+ or CD8+ T cells
Subjects Population pp65+IE-1 stimulation, 
HIV- vs HIV+ subjects
pp65+IE-1 vs Gag+Env 
stimulation, HIV+ 
subjects
pp65+IE-1 stimulation, 
HIV- vs HIV+ subjects
pp65+IE-1 vs Gag+Env 
stimulation, HIV+ 
subjects
All (CD4+ IFNγ+) <.000011 0.00120 0.08193 0.11850
(CD4+ IFNγ+ IL-2+) <.00001 0.00310 0.99855 0.01903
(CD8+ IFNγ+) 0.00001 0.00002 0.05149 <.00001
(CD8+ IFNγ+ IL-2+) 0.82219 0.06415 0.80507 0.00760
Non-ART only (CD4+ IFNγ+) <.00001 0.00016 0.05508 0.01023
(CD4+ IFNγ+ IL-2+) <.00001 0.00184 0.98033 0.02026
(CD8+ IFNγ+) 0.99841 0.00001 0.94575 0.00008
(CD8+ IFNγ+ IL-2+) 0.18590 0.09745 0.57196 0.05185
1 All results are expressed as p-values. p < 0.05 was considered significant (shown in bold).AIDS Research and Therapy 2006, 3:18 http://www.aidsrestherapy.com/content/3/1/18
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ship between phenotype and IL-2 production could be
seen in CMV-responsive CD8+ T cells of healthy donors
(Figure 6), that relationship was disrupted in HIV
responses. These latter displayed a pervasive lack of IL-2
production among CD8+ T cells of all phenotypes. Never-
theless, there was a significant correlation between the
number of CD8+ IL-2+ T cells and the number of CD8+
terminal effector T cells (CD27- CD28- CD45RA+)
responding to HIV (Figure 7). This is despite the fact that
the terminal effector cells are least likely to actually pro-
duce IL-2 (Figure 6). In fact, IL-2 production was most cor-
related with CD28 expression, among the three memory/
effector markers used in this study (data not shown), in
agreement with previous work demonstrating that CD28
expression is important for IL-2 production [3]. The corre-
lation of terminal effector cell numbers with IL-2-produc-
ing cells is thus unexpected.
Conclusion
In this paper, we have confirmed two important defects in
cellular immunity to HIV that were previously reported
only in separate studies. Furthermore, we have unexpect-
edly shown that these two defects are quantitatively corre-
lated, suggesting a mechanistic involvement of IL-2
production in the differentiation of CD8+ effector T cells.
This has implications for immunotherapy and immuno-
monitoring of HIV disease, as it suggests that the preserva-
tion of HIV-specific CD8+ IL-2 production is likely to be
important for maintaining effector T cell-mediated viral
control.
Methods
Study subjects
HIV-positive subjects
Nineteen subjects (called "progressors" in this study) were
selected from an ongoing study at the San Francisco Gen-
eral Hospital and San Francisco Veterans Affairs Medical
Center (Study of the Consequences of the Protease Inhib-
itor Era [SCOPE]). Progressors (Table 1) had a decrease in
CD4+ T cell counts to less than 500 cells/mm3 during the
chronic stage of their infection, and had persistent plasma
HIV RNA levels >2000 copies/ml. Current CD4 count,
duration of therapy, specific therapies, and self-reported
duration of HIV infection were not factors for exclusion
from this study. All HIV-positive subjects were also CMV-
positive.
HIV-negative subjects
Twenty CMV-positive subjects (Table 1) were selected
from BD Biosciences' in-house pool of blood donors. All
subjects were adults and were asymptomatic and healthy
at the time of sample collection.
Informed consent was obtained from subjects, and
human experimentation guidelines of the US Department
of Health and Human Services and of all involved institu-
tions were followed.
Viral load and absolute cell count determination
HIV-positive subjects
Plasma HIV RNA levels were determined by the branched
DNA (bDNA) amplification technique (Quantiplex® HIV
Production of IL-2 by various phenotypes of CD8+ T cells Figure 6
Production of IL-2 by various phenotypes of CD8+ T cells. 
Each bar represents the mean (for 20 HIV-negative or 19 
HIV-positive subjects) of the ratios of IL-2 to IFNγ produc-
tion for each of the phenotypes, as listed at the bottom of 
the figure. Phenotypes are arranged by amount of IL-2 pro-
duction; naïve cells (CD27+ CD28+ CD45RA+) were not 
analyzed as they are not expected to make IFNγ. Error bars 
represent SEM. Results are shown for the response of HIV-
negative subjects to pp65+IE-1 stimulation (top), the 
response of HIV-positive subjects to pp65+IE-1 stimulation 
(middle), and the response of HIV-positive subjects to 
Gag+Env stimulation (bottom).
R
a
t
i
o
 
o
f
 
I
L
-
2
+
 
t
o
 
I
F
N
γ
+
 
c
e
l
l
s
CD27: + - - + + - -
CD28: +  +  +  ----
CD45RA: --+  -+  -+
0.0
0.1
0.2
0.3
0.0
0.1
0.2
0.3
0.0
0.1
0.2
0.3
HIV- subjects
pp65+IE-1
HIV+ subjects
pp65+IE-1
HIV+ subjects
Gag+EnvAIDS Research and Therapy 2006, 3:18 http://www.aidsrestherapy.com/content/3/1/18
Page 11 of 14
(page number not for citation purposes)
RNA, version 3.0, Chiron Corporation, Emeryville, CA).
CD4 and CD8 counts were obtained using the Multitest
assay with a FACSCalibur flow cytometer and Multiset
software (BD Biosciences, San Jose, CA).
Correlation analyses of IL-2 production and effector cell differentiation Figure 7
Correlation analyses of IL-2 production and effector cell differentiation. A. Top, the absolute number of the HIV-specific CD8+ 
IFNγ+ IL-2+ T cells is plotted against the absolute number of the HIV-specific CD8+ terminal effector T cells (CD27- CD28- 
CD45RA+); bottom, the same correlation, but including CMV-specific responses of the same subjects. B. Top, the absolute 
number of all HIV-specific IFNγ+ IL-2+ cells (both CD8+ and CD4+) is plotted against all HIV-specific terminal effector T cells; 
bottom, the same correlation, but including CMV-specific responses of the same subjects. In all correlations, each square rep-
resents a single subject's CMV or HIV response.
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HIV-negative subjects
CD4 and CD8 absolute cell counts were determined using
TruCount "Hi" beads and TriTest CD3 FITC/CD4 PE/
CD45 PerCP antibodies (BD Biosciences) [28].
Sample preparation and activation
Individual peptides of 15 amino acid residues, overlap-
ping by 11 amino acids each, were designed to span the
sequences of CMV pp65 (138 peptides) and IE-1 (Imme-
diate Early-1; 120 peptides), and HIV p55 Gag (SF2 strain,
127 peptides) and env (MN strain, 204 peptides). Peptide
mixes (SynPep, Dublin, CA) were dissolved in DMSO at
stock concentrations of 0.7–1.0 mg/ml per peptide. The
mixes were used at a final concentration of 1.2–2 μg/ml
per peptide [29].
PBMC were isolated from heparinized whole blood
within eight hours of collection, by centrifugation in CPT
tubes (BD Vacutainer, Franklin Lakes, NJ). PBMC were
washed and resuspended in RPMI with 10% fetal bovine
serum (cRPMI) at 5 × 106 – 1 × 107 cells/ml. Five hundred
microliters of PBMC in cRPMI were aliquoted into wells
of a 24-well deep-well plate (Qiagen, Valencia, CA). CMV
pp65+IE-1 or HIV p55 Gag+Env peptide mixes were
added to the appropriate wells, plus brefeldin A (BD Bio-
sciences) at a final concentration of 10 μg/ml; an addi-
tional well received only brefeldin A as a negative control.
The plate was incubated for six hours at 37°C, then held
overnight at 18°C.
Sample processing and staining
Cell-surface markers such as CD3, CD4, and CD8 can be
stained before or after cell fixation and permeabilization.
We stained for these markers before fixation, since this
enhanced resolution of positive and negative popula-
tions. Although some down-modulation of these markers
occurred on activated cells, we were still able to include
down-modulated cells within the positive gate.
Details of the cytokine flow cytometry protocol can be
found on the Maecker Lab weblog [30]. Briefly, cells were
stained for 60 minutes with CD28 PerCP-Cy5.5, CD45RA
PE-Cy7, CD27 APC, CD8 APC-Cy7, CD3 Pacific Blue, and
CD4 AmCyan (all from BD Biosciences). Samples were
treated with BD FACS Lysing Solution followed by BD
FACS Permeabilizing Solution 2, washed, then stained
with IFNγ FITC and IL-2 PE (BD Biosciences) for 60 min-
utes. They were then washed and resuspended in BD Sta-
bilizing Fixative (BD Biosciences) and held at 4°C until
sample acquisition.
For each donor, 100 μl of PBMC remained unstained, for
use when establishing PMT voltage settings. Eight tubes
containing BD CompBeads Anti-Mouse Ig,κ and Negative
Control Compensation Particles (BD Biosciences) were
each stained with one of the eight mAbs listed above. The
beads were treated identically to the PBMC samples,
except that all stains (including cytokines) were added
during the "surface staining" step.
Sample acquisition and analysis
Flow cytometry was performed using an LSRII (BD Bio-
sciences) equipped with blue (488 nm), red (633 nm),
and violet (405 nm) lasers. Compensation settings were
established using the AutoComp option of FACS DiVa
software (BD Biosciences). An average of 2 × 106 CD3+
cells were collected for HIV-negative subject samples, and
an average of 4 × 105 CD3+ cells were collected for HIV-
positive subject samples.
Data were analyzed with FACS DiVa software. Where
appropriate, data were displayed with a transformation
that allows for improved visualization of events at the
lower end of the log scale (BiExponential analysis). A gat-
ing hierarchy was designed as shown in Figure 1. The
result of this gating strategy was 32 possible phenotypes of
antigen-responsive T cells.
Dead cells were excluded by use of a side scatter gate and
by gating on single-stained cells for either CD4 or CD8.
Non-viable cells generally bound both of these antibodies
non-specifically.
Cytokine production in the absence of stimulation was
low, and largely restricted to CD8+ terminally differenti-
ated effector cells (CD27- CD28- CD45RA+ [12,15,31-
37]; Fig 5A, black bars). As such, backgrounds were not
subtracted from the responses shown in the grey bars.
Responses ≥ 100 cells/ml were significantly higher than
background for all phenotypes except the terminal effec-
tor cells mentioned above.
Data were batch-analyzed to ensure uniform gating, and
statistics files were uploaded to a database created for this
study. This database enabled selection of particular data
subsets of interest, which were then downloaded into
Microsoft Excel and GraphPad Prism (GraphPad, San
Diego, CA) for statistical analysis and graphing. Statistical
comparisons between HIV-positive and HIV-negative sub-
jects were performed using a Mann Whitney test. Statisti-
cal comparisons between different stimulations of HIV-
positive samples were performed using a Wilcoxon signed
rank test. Values of p < 0.025 were considered statistically
significant, to correct for the two sets of comparisons
listed above.
ANOVA (Table 2) were conducted using the Open Source
statistics package R [38]. For each of the four cell popula-
tions (CD4+ IFNγ+, CD4+ IFNγ+ IL-2+, CD8+ IFNγ+, or
CD8+ IFNγ+ IL-2+), a separate model was fit in which theAIDS Research and Therapy 2006, 3:18 http://www.aidsrestherapy.com/content/3/1/18
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response was the absolute cell count for each subject and
the main effect was the eight combinations of the markers
CD27, CD28, and CD45RA. Two contrasts were added to
test specifically whether or not the average numbers for
each phenotype followed the same pattern for HIV-posi-
tive CMV versus HIV-negative CMV, and for HIV-positive
CMV versus HIV-positive HIV responses. The p-values
reported were for the interaction term between each of
these contrasts and the main effect for phenotype. A p-
value < 0.05 indicates that the two subject groups had sig-
nificantly different patterns in the numbers of cells of each
phenotype.
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